Insider trade

Officer sold ~$278K of JAZZ shares in the open market

Traded Jun 10, 2026 · Filed Jun 13, 2026

Why it stands out

Jazz Pharmaceuticals's & Chief Legal Officer sold $278K of Jazz Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$278,196

Shares × reported transaction price

Timing vs results

36 days after results of May 5, 2026, 54 days before results of Aug 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.0%	−1.4%	−0.7%
30 days	+3.8%	0.0%	+3.8%
90 days	+6.6%	+0.8%	+5.8%

Past results only. Not a forecast.

This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
The Reporting Person acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.

Scheduled in advance3mo ago

3mo ago

Routine share withholding; mechanical by default.

3mo ago

Routine share withholding; mechanical by default.